Literature DB >> 10997073

The relationship between survival and cell proliferation index in squamous cell carcinoma of larynx.

A Pérez Carro Ríos1, T García Caballero, A Lozano Ramírez, M D Arias Santos, A Soto Varela, J Forteza Vila, T Labella Caballero.   

Abstract

Cell proliferation index is one of the most important factors in assessment of growth and progression of tumours. At present, the most suitable method of determining cell proliferation is by means of immunohistochemical techniques which use the monoclonal anti-body MIB-1 which reacts against Ki-67, a protein released only in the proliferation phases of the cell cycle. In this study, 44 patients diagnosed with squamous cell carcinoma of the larynx were analysed retrospectively and different macroscopic and microscopic parameters were assessed, such as MIB-1 in relation to the current status of the patient. A statistically significant relationship was found between the cell proliferation index, the histological grade of differentiation and the clinical evolution of the illness.

Entities:  

Mesh:

Year:  2000        PMID: 10997073

Source DB:  PubMed          Journal:  Rev Laryngol Otol Rhinol (Bord)        ISSN: 0035-1334


  3 in total

1.  p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival.

Authors:  M Re; A Zizzi; L Ferrante; D Stramazzotti; G Goteri; F M Gioacchini; F Olivieri; G Magliulo; C Rubini
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-09       Impact factor: 2.503

2.  Immunoexpression of p53, Ki-67 and E-cadherin in basaloid squamous cell carcinoma of the larynx.

Authors:  María J Rodríguez Tojo; Francisco J García Cano; Juan C Infante Sánchez; E Velázquez Fernández; José M Aguirre Urízar
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

3.  Prognostic significance of Ki-67 expression for patients with laryngeal squamous cell carcinoma primarily treated by total laryngectomy.

Authors:  Mustafa Fuat Acikalin; Ulkü Oner; Nilüfer Tel; Ozgül Paşaoğlu; Hamdi Cakli; Ertuğrul Colak
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-11-06       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.